1α,25-dihydroxyvitamin d3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms

Endocrinology

Volumn 141, Issue 7, 2000, Pages 2548-2556

  Zhao, Xiao Yan ^a   Peehl, Donna M ^a   Navone, Nora M ^b   Feldman, David ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; CALCITRIOL; MESSENGER RNA; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CALCITRIOL RECEPTOR; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DRUG DERIVATIVE; LIGAND; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

ARTICLE; BINDING AFFINITY; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; HORMONE ACTION; HUMAN; HUMAN CELL; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; CELL DIVISION; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; UPREGULATION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS; CELL DIVISION; HUMANS; LIGANDS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL; UP-REGULATION; VITAMIN D;

EID: 85047683799     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.7.7549     Document Type: Article

References (39)

1. Newly identified actions of the vitamin D endocrine system
2. Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential
3. Vitamin D: Anticancer and differentiation
4. Vitamin D: Metabolism and action
5. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed
6. Cloning and expression of fulllength cDNA encoding human vitamin D receptor
7. 3
8. 3 receptors and actions in human prostate cancer cell lines
9. 3 on primary cultures of human prostatic cells
10. 3 actions in LNCaP human prostate cancer cells are androgen-dependent
11. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system
12. 3 and 9-cis retinoic acid m LNCaP human prostate cancer cells
13. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a
14. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity
15. 3 in seven human prostatic carcinoma cell lines
16. 3 in the human prostatic carcinoma cell line ALVA-31
17. Vitamin D and prostate cancer: Biologic interactions and clinical potentials
18. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
19. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1α,25dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate
20. 3 in the androgen-dependent LNCaP cells
21. 1
22. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
23. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
24. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
25. LNCaP model of human prostatic carcinoma
26. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
27. kip1 in androgen-induced cell cycle arrest
28. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA
29. Androgen-repressed phenotype in human prostate cancer
30. Establishment of two human prostate cancer cell lines derived from a single bone metastasis
31. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
32. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
33. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding
34. A study of conditions and mechanisms of the diphenyl amine colorimetric estimation of deoxyribonucleic acid
35. Characterization and expression of a cDNA encoding the human androgen receptor
36. 3 in cultured mouse osteoblast-like cells-modulation by changes in receptor level
37. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
38. Isolation of a human prostate carcinoma cell line (DU 145)
39. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: Comparative analyses of MDA PCa 2a with established cell lines